BioSpectrum the business of Bio & Health Sciences ASIA EDITION

myAirvo significantly benefits COPD Patients

April 20, 2018 | News

The trial is the largest study of this treatment length to have been conducted in a home environment and was led by researchers Line Storgaard and Dr Ulla Weinreich.



Singapore- Fisher & Paykel Healthcare Corporation Limited announced that new research has been published in the *International Journal of COPD* which demonstrates significant benefits of nasal high flow therapy for COPD patients using Fisher & Paykel Healthcare's myAirvo device.

The study, a randomised controlled trial undertaken in Denmark, investigated the long-term effects of nasal high flow therapy for COPD patients already being treated with long-term oxygen therapy.

The trial is the largest study of this treatment length to have been conducted in a home environment and was led by researchers Line Storgaard and Dr Ulla Weinreich. It followed 200 patients with COPD on long-term oxygen for 16 hours or more per day over a period of one year.

Vice President - Products & Technology at Fisher & Paykel Healthcare, Andrew Somervell said, "It is positive to see such convincing outcomes for patients with COPD. We expect this study to increase clinical interest in the myAirvo home respiratory device and encourage clinical change and adoption around the world."

As a result of the positive outcomes of this pilot trial, a larger multi-centre trial has commenced.